4 Experimental Ebola Therapies Approved for Use in Congo

Share this content:
4 Experimental Ebola Therapies Approved for Use in Congo
4 Experimental Ebola Therapies Approved for Use in Congo

WEDNESDAY, Aug. 22, 2018 (HealthDay News) -- Four more experimental treatments for Ebola virus have been approved by the Congo health ministry for use in an outbreak of the deadly infectious disease in the country's northeast.

The treatments are ZMapp, Remdesivir, Favipiravir, and Regn3450 - 3471 - 3479. On Aug. 11, health officials began using the experimental treatment mAb114 on 10 patients, and the ministry says they are doing well, the Associated Press reported.

The most recent Ebola outbreak in Congo was declared in Mangina in North Kivu province on Aug. 1. There have been 75 confirmed Ebola cases and 27 probable ones. Of 59 reported deaths, 32 have been confirmed as Ebola, according to the health ministry.

The ministry said that since Aug. 8, more than 1,600 people have been vaccinated in Mabalako and Beni in North Kivu province and in Mandima in Ituri province, the AP reported.

AP News Article
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Global Prevalence of Insufficient Activity 27.5 Percent

Global Prevalence of Insufficient Activity 27.5 Percent

Levels of insufficient physical activity stable between 2001, 2016; increase seen in high-income countries

HTN Tx Intensification Common Upon Discharge in U.S. Vets

HTN Tx Intensification Common Upon Discharge in U.S. ...

Fourteen percent of older adults admitted to hospital for non-cardiac conditions had intensification of tx

Quarterly Canakinumab Reduces Risk for Gout Attacks

Quarterly Canakinumab Reduces Risk for Gout Attacks

Doesn't affect serum uric acid levels over time, but targets interleukin-1β

is free, fast, and customized just for you!




Already a member?

Sign In Now »